|
The Breast International Group (BIG) is an international non-profit organisation for academic breast cancer research groups from around the world.
By encouraging interaction and cooperation between its members and other academic networks, and by collaborating with, but working independently from, the pharmaceutical industry, BIG’s mission is to facilitate breast cancer research internationally in order to reduce the wasteful duplication of effort, advance knowledge in the field, and optimally serve those affected by the disease.
Created by leading European opinion leaders in 1996, BIG now constitutes a network of 47 groups based in Europe, Canada, Latin America, Asia and Australasia. These research entities, which coordinate the BIG trials, are in turn tied to approximately 3000 specialised hospitals and research centres around the world.
BIG is also the founder and coordinator of the TRANSBIG consortium for translational research.
Click here to access the BIG website.
|
TRANSBIG is a translational research network of 40 world-class institutions in 22 countries managed by the BIG-TRANSBIG Headquarters in Brussels.
The key to individualising treatment for cancer lies in finding a way to quickly “translate” the discoveries about human genetics made by laboratory scientists into tools that physicians can use to help make decisions about the way they treat patients. TRANSBIG is devoted specifically to this type of research in breast cancer.
TRANSBIG was created to improve high-level collaboration by bringing together organisations with expertise that range from specialisation in cutting-edge biomedical technologies to patient advocacy.
TRANSBIG’s first project is a clinical trial called MINDACT (“Microarray for Node Negative and 1 to 3 Positive Node Disease may Avoid Chemotherapy”).
Click here to access the TRANSBIG website.
|